ITM Isotopen Technologien Mᅢテᅡᄐnchen AG Revenue and Competitors

Garching near Munich, Germany

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • ITM Isotopen Technologien Mᅢテᅡᄐnchen AG's estimated annual revenue is currently $49.6M per year.(i)
  • ITM Isotopen Technologien Mᅢテᅡᄐnchen AG's estimated revenue per employee is $201,000

Employee Data

  • ITM Isotopen Technologien Mᅢテᅡᄐnchen AG has 247 Employees.(i)
  • ITM Isotopen Technologien Mᅢテᅡᄐnchen AG grew their employee count by 52% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$89.4M4459%N/AN/A
#2
$25.7M128-3%N/AN/A
#3
$41.6M20725%N/AN/A
#4
$120.2M42717%$446.2MN/A
#5
$44.4M22146%N/AN/A
#6
$49.6M24752%N/AN/A
#7
$21.9M109-1%N/AN/A
#8
$14.9M74-3%N/AN/A
#9
$26.7M13325%N/AN/A
#10
$19.9M991%N/AN/A
Add Company

PASSION FOR PRECISION. ITM Isotopen Technologien Mᅢテᅡᄐnchen AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITMᅢᄁ¬ツᆲ¬トᄁs isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBetaᅢツᅡᆴ of ITMᅢツᅡᄡs subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBetaᅢツᅡᆴ respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITMᅢᄁ¬ツᆲ¬トᄁs main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. Therapies in Precision Oncology. For more information about ITM, please visit: www.itm.ag Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines

keywords:N/A

N/A

Total Funding

247

Number of Employees

$49.6M

Revenue (est)

52%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ITM Isotopen Technologien Mᅢテᅡᄐnchen AG News

2021-09-09 - ITM to Host Virtual Symposium at the ESMO Congress 2021 with Key Neuroendocrine Tumor Experts on September 17, 2021

ITM AG, a leading radiopharmaceutical company, today announced that it will host a virtual industry satellite symposium titled, “A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy” at the European Society of Medica ...

2021-06-10 - ITM : Announces EUR 25 Million (USD 30 M) Private Equity Financing to Support Advancement of Proprietary Precision Oncology Pipeline

ITM AG, a leading radiopharmaceutical company, announced today the close of a private equity financing round from existing and new investors, related and connected parties to Portland Holdings, along with FRIBA Investment, raising a total of EUR 25 million (USD 30 million). The funding will supp ...

2021-05-20 - ITM to Host Virtual Symposium on “New Approaches for Targeted Radionuclide Therapy in Precision Oncology” with Key Opinion Leaders on Friday, June 4th, 2021 in Parallel to 2021 ASCO Annual Meeting

ITM AG, a leading radiopharmaceutical company, today announced that it will host a virtual symposium titled, “New Approaches for Targeted Radionuclide Therapy in Precision Oncology” as an ancillary event in parallel to the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The sym ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$76.4M38012%N/A